



MEMORANDUM

To: Donna E. Shalala, President

From: Tomas A. Salerno
Chair, Faculty Senate

Date: February 27, 2015

Subject: Faculty Senate Legislation #2014-22(B) – Establish an HIV/AIDS Institute at the University of Miami Miller School of Medicine

The Faculty Senate, at its February 25, 2015 meeting, voted unanimously to approve the establishment an HIV/AIDS Institute at the Miller School of Medicine. This Institute had previously received provisional status and was operating under these guidelines. As noted in the proposal, currently the HIV/AIDS initiatives at the Miller School are robust but fragmented. The goal of this interdisciplinary Institute is to meet the urgent need for an integrated, interdisciplinary institute that offers the expertise, infrastructure, and resources necessary to organize and energize HIV/AIDS science and advance translational and clinical research and education in the field at the Miller School.


This legislation is now forwarded to you for your action.

TAS/rh

Enclosure

cc: Thomas LeBlanc, Executive Vice President and Provost
Pascal Goldschmidt, Sr. Vice President and Dean, Miller School of Medicine
Mario Stevenson, Director, HIV/AIDS Institute, Miller School of Medicine
Elaine Van der Put, Presenter, Research Assistant Professor, Miller School of Medicine

CAPSULE: Faculty Senate Legislation #2014-22(B) – Establish an HIV/AIDS Institute at the University of Miami Miller School of Medicine

APPROVED:  DATE: 03/06/2015
(President's Signature)

OFFICE OR INDIVIDUAL TO IMPLEMENT: Dean Goldschmidt

EFFECTIVE DATE OF LEGISLATION: IMMEDIATELY
(if other than June 1 next following)

NOT APPROVED AND REFERRED TO: _____

REMARKS (IF NOT APPROVED): _____

**Proposal for the Establishment of the
HIV/AIDS Institute
at the University of Miami Leonard M. Miller School of Medicine**

1. BACKGROUND

This proposal seeks to formally establish an interdisciplinary HIV/HIV/AIDS Institute at the University of Miami Leonard M. Miller School of Medicine. The Institute will be called the HIV/AIDS Institute.

Acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by infection with the human immunodeficiency virus (HIV). AIDS was first recognized by the Centers for Disease Control and Prevention (CDC) in 1981 and its cause—HIV infection—was subsequently identified in the early part of the same decade. From its discovery to 2012, AIDS has caused an estimated 36 million deaths and approximately 35.3 million people are living with HIV globally. HIV/AIDS is considered a pandemic and represents a significant challenge in global health.

The Miller School's commitment to HIV/AIDS research and treatment can be traced back to the early 1980s when UM doctors began to see patients with immune system disorders. Although the Miami patients included homosexual men, it was significant that the patients also included heterosexual men and women from Haiti. In March 1983, the UM physicians published the first description of AIDS in heterosexual patients in the *Annals of Internal Medicine*.

Beginning in 1988, the Miller School created the UM Comprehensive AIDS Program (CAP). This primarily clinical program coordinates data collection, HIV surveillance, community outreach, and funding for HIV care from sources such as Ryan White Title I and the State of Florida. In 2007, UM's extensive research efforts in HIV/AIDS were recognized with a five-year, \$3.6 million grant by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to establish a Developmental Center for AIDS Research (DCFAR). With that award, UM became home to the first NIH-funded AIDS research center in Florida. The DCFAR achieved designation as a full Center for AIDS Research (CFAR) in 2013 and joined the 18 other academic centers nationally as a leader in HIV/AIDS research.

There is an urgent need for an integrated, interdisciplinary institute that offers the expertise, infrastructure, and resources necessary to organize and energize HIV/AIDS science and advance translational and clinical research and education in HIV/AIDS at the Leonard M. Miller School of Medicine. The HIV/AIDS initiatives at the Miller School are robust but fragmented. The creation of an HIV/AIDS Institute will position the HIV/AIDS programs at the Miller School for the next chapter in their impressive history.

2. MISSION

The HIV/AIDS Institute coordinates and integrates all AIDS research and clinical activities at the Miller School of Medicine. The mission is to stimulate innovation, support interdisciplinary collaboration and create synergy among the School's diverse HIV/AIDS initiatives and programs with

the goal of speeding significant advances in understanding, preventing and treating HIV infection and AIDS associated malignancies.

Although the HIV/AIDS Institute will initially be based at the School of Medicine, it is anticipated that, over time, the HIV/AIDS Institute will become a locus for the establishment and development of fruitful collaborations across other University Schools and Colleges by bringing together and matching interests and expertise in an intentional and productive manner. At such time as those collaborations are established, the HIV/AIDS Institute would be taken through the proper University procedure for consideration as a University Institute.

3. ORGANIZATION AND MEMBERSHIP

Organization

The proposed HIV/AIDS Institute will be led by a Director, who is appointed and reviewed annually by the Dean of the Miller School of Medicine. The HIV/AIDS Institute will initially consist of 4 components – a Research Arm, a Clinical Care and Outreach Arm, a unit focused on statewide initiatives, and a Philanthropic Arm. Each unit is headed by an Associate Director, who is appointed by the Director, in consultation with the Dean of the Miller School. Each Associate Director is reviewed annually by the Director. This organization is explained in more detail below.

HIV/AIDS Institute Director:

The Director is responsible for articulating and representing the vision of the HIV/AIDS Institute as well as the overall leadership and management of the Institute, including the component parts. Dr. Mario Stevenson, Ph.D., Chief, Division of Infectious Disease is the proposed Director of the HIV/AIDS Institute. An internationally recognized leader in the field of HIV/AIDS, Dr. Stevenson previously directed the Center for AIDS Research at the University of Massachusetts Medical School and is currently co-Director of the UM CFAR.

Research:

Center for AIDS Research

The Center for AIDS Research (CFAR) is an NIH-funded initiative designed to enhance and coordinate UM's AIDS research activities in basic, clinical, and behavioral/social sciences. As such, the CFAR will form the Research Arm of the HIV/AIDS Institute and will foster and promote growth in AIDS and HIV related research programs, including education and mentorship, at UM and at partnering institutions. Inclusion in the HIV/AIDS Institute will not alter the existing administrative structure of the CFAR. Dr. Savita Pahwa will continue to serve as CFAR Director with Drs. Stevenson and Margaret Fischl of the Division of Infectious Diseases as Co-Directors. The current CFAR administrative component (and associated facilities and administrative (F&A) costs currently returned to the CFAR) will be leveraged for the HIV/AIDS Institute.

Prevention Sciences

The focus on prevention science will be a key part of the Research Arm of the HIV/AIDS Institute at the University of Miami Miller School of Medicine, and will expand on current and ongoing activities. These activities emphasize epidemiologic, intervention and biomedical studies addressing primary and secondary prevention needs of people at risk and living with HIV. Specifically:

- **Primary HIV Prevention** in at risk population with special emphasis to vulnerable populations. This includes ethnic and sexual minorities and substance abuse populations. The main areas of interest are pre-exposure prophylaxis, testing and behavioral interventions addressing the needs of these populations.
- **Secondary HIV prevention** in vulnerable HIV infected populations. These include ethnic minorities, substance abusers, low socioeconomic status and hospitalized HIV patients. The main areas of interest are linkage, retention and re-engagement to care.

The prevention science and activities are enhanced by

- Promoting active involvement of south Florida community-based organizations to collaborate with the University of Miami.
- Providing UM and Miami-Dade County community investigators with consultation and resources to enhance recruitment and retention in community and clinic-based settings of vulnerable HIV at risk or infected populations, with special emphasis on the most vulnerable and hard to reach populations.
- Expanding the opportunities for prevention scientists to collaborate with clinical and laboratory scientists.

PhD Program in Prevention Science and Community Health

The purpose of the proposed interdisciplinary PhD program in prevention science and community health is to train the next generation of researchers who are committed to reducing the mortality and morbidity attributable to behaviorally based, preventable causes of illness, disability, and death such as HIV/AIDS – and to promoting community health – in the United States and abroad. We propose to train doctoral students whose expressed objectives are to join the prevention research workforce. There is already a great deal of prevention-related expertise in the Department of Public Health Sciences, where the proposed Ph.D. program would be housed, as well as in other schools and departments around the University of Miami. Doctoral students will have ready access to faculty who can train students in cutting-edge prevention models and methods as well as community health. The time is right for such an endeavor.

The importance of prevention is underscored by the leading causes of death between 1990 and 2000 (Mokdad, Marks, Stroup, & Gerberding, 2004). Of the top nine causes of death during that time, seven were behaviorally based and preventable: tobacco use, poor diet and physical inactivity, alcohol consumption, motor vehicle crashes, firearm use, unsafe/unprotected sexual behavior, and illicit drug use. The [National Prevention Strategy](#), an important component of the Affordable Health Care Act, was adopted by the Obama Administration in 2011 as a way of addressing the problem of preventable causes of illness and death. The priorities within the National Prevention Strategy include creating healthy and safe communities, eliminating health disparities, providing clinical and community prevention services, and empowering people. Similarly, the University of Miami Miller School of Medicine's mission includes personalized preventive care and health promotion, integration of prevention and wellness principles into medical practice, emphasizing a scholarly approach to wellness and health, and promoting health equity across various segments of the population. These principles dovetail nicely with the field of prevention science and community

health, and with the expertise among the faculty within the UM Department of Public Health Sciences, and specifically within the Division of Prevention Science and Community Health. *The proposed PhD program's curriculum can serve as a resource for training faculty, post-doctoral fellows, and other HIV/AIDS Institute affiliates interested in developing, adapting, and translating effective HIV preventive intervention into community practice.*

Clinical Care and Outreach:

Comprehensive AIDS Program

At UM, the clinical care of individuals living with HIV is coordinated through the Comprehensive AIDS Program (CAP). The Clinical Care and Outreach Arm of the HIV/AIDS Institute will expand on the CAP infrastructure to combine the current UM activities in HIV/AIDS clinical care operations with those of partnering institutions and community based clinics. By doing so, the creation of the HIV/AIDS Institute will greatly advance UM's clinical impact in HIV/AIDS while enlarging a patient base from which to recruit subjects for research studies. Inclusion in the HIV/AIDS Institute will not alter the existing administrative structure of the CAP. Dr. Michael Kolber, the Director of the Comprehensive AIDS Program, will serve as the Associate Director of the Clinical Care and Outreach Arm of the HIV/AIDS Institute.

Statewide Initiatives:

Under Dr. Stevenson's leadership, the 2014 State of Florida legislature has designated \$1,000,000 in nonrecurring funds from the General Revenue Fund for academic and research institutions designated as Centers for AIDS Research (CFAR) by the National Institutes of Health with a goal to enhance high quality HIV/AIDS research projects conducted in response to the health needs of Florida's citizens (Specific Appropriation 491). This is the first step in establishing a state-funded HIV/AIDS grant program that would support all aspects of basic and clinical HIV/AIDS research at UM and other Florida research institutions. Similar to the Florida Biomedical Research Program, the objective is to create a state funding mechanism to support innovative and high impact AIDS research projects so that they can go on to compete for Federal and other grant funds. Florida has been heavily impacted by the HIV/AIDS epidemic. The state continues to rank third in the nation in the cumulative number of AIDS cases (126,581 in 2012) and second in the nation in the cumulative number of HIV cases (49,058 in 2012). The Florida legislature has a history of earmarking state funds to support biomedical research in specific areas that affect Floridians and for which federal grant opportunities exist (Florida Biomedical Research Program). The objectives of the state funding initiative within the HIV/AIDS Institute are to (1) lead the effort to create the State program, and (2) once formulated, to provide administrative and scientific oversight for the initiative. In his role as Director, Dr. Stevenson will continue to lead the effort to establish recurring funds for the program. As the statewide efforts grow, it is anticipated that the CFAR administrative structure will be expanded to meet the needs of the state program, including the designation of an Associate Director.

Philanthropy:

The lack of a nidus for HIV/AIDS creates a significant hurdle for developing philanthropy. The HIV/AIDS Institute will include a philanthropic arm that, in close coordination with Medical Development, will enhance the visibility of HIV/AIDS research and clinical efforts at UM and identify philanthropic sources that support the missions of the HIV/AIDS Institute. Dr. Stevenson has

worked closely with the Palm Beach Infectious Diseases Institute (PBIDI), a regional non-profit that raises funds for infectious diseases research, and such a partnership with PBIDI is critical for the success of the HIV/AIDS Institute's fundraising efforts. Dr. Istvan Krisko, Director of the PBIDI, will serve as the Associate Director, UM/PBIDI and will work with Medical Development to identify prospective donors, secure gifts, and ensure that funds are allocated in a way that has the maximum impact on HIV/AIDS research and clinical care while meeting the donor's vision for the gift. Under such a structure, philanthropic efforts may be made using entity names such as "HIV/AIDS Institute," "HIV/AIDS Institute," and "Infectious Diseases Institute." An agreement is underway between Medical Development and the PBIDI for this purpose.

Administrative Support:

The HIV/AIDS Institute will leverage existing administrative staff within the CFAR and, as pilot funding initiatives grow, will employ additional administrative support personnel to administer those pilots. If the CFAR is not renewed beyond 2019, administrative support will be subsidized by philanthropic dollars

HIV/AIDS Institute Internal Advisory Board:

The HIV/AIDS Institute Internal Advisory Board (Board) meets quarterly to provide feedback and consultation to the Institute Director regarding the Institute's activities, including scientific progress, clinical care, community connections, needs, and new initiatives. The Board will be comprised of the HIV/AIDS Institute Director and the Associate Directors of each component. Other Miller School of Medicine or University leaders will be invited at the discretion of the HIV/AIDS Institute Director on an as needed basis.

HIV/AIDS Institute Governance Committee:

The HIV/AIDS Institute Governance Committee (Committee) meets annually to provide feedback and consultation to the HIV/AIDS Institute Director regarding the Institute's progress and future plans, including development and strategic planning. The Committee will be comprised of the HIV/AIDS Institute Director, the Dean of the Miller School of Medicine, a representative from the Palm Beach ID Institute appointed by the Director, a representative from the CFAR External Advisory Board, and two external luminaries – one world class expert in fundamental aspects of HIV/AIDS biology and one international leader in HIV/AIDS clinical care or patient/community advocacy. Other Miller School of Medicine or University leaders will be invited at the discretion of the HIV/AIDS Institute Director on an as needed basis.

Membership

The HIV/AIDS Institute will not have a formal membership process. The Institute openly seeks and supports research and activities related to its mission and does not have formal members. Per University of Miami policy all faculty and voluntary physicians are required to have an appointment through a Leonard M. Miller School of Medicine Department. University faculty interested in affiliating with the Institute can contact Dr. Stevenson. Membership in the HIV/AIDS Institute or participation in HIV/AIDS Institute activities will not impact how indirect costs (IDCs) held by that member are distributed. IDCs of HIV/AIDS Institute members will remain with that member's primary departmental affiliation unless otherwise negotiated and agreed upon.

5. Space


The creation of the HIV/AIDS Institute does not require any new space allocation.

6. Funding Sources and Budget Projections

The HIV/AIDS Institute is being initially supported by IDCs from the CFAR grant and a gift from the PBIDI. No additional dollars are required from UM. The HIV/AIDS Institute predicts that a more directed and consistent approach to philanthropy will grow the funds already available via the PBIDI. The current agreement includes a \$900,000 allocation from PBIDI. All members are expected to seek external funding for their research, thus there are high expectations for significant growth in sponsored funding. The State funds will be used to support collaborative research at UM and at partnering Florida institutions with CFAR designation. The table below illustrates the near-term financial projections for HIV/AIDS Institute.

Budget information redacted

Proposed Table of Organization



<u>Letter of Support</u>	<u>Title</u>	<u>Approval/ Support Letter</u>
Carl Schulman, M.D., M.S.P.H., Ph.D.	Chair, Medical Faculty Council	Approval Letter
Pascal J. Goldschmidt, M.D.	Sr. Vice President for Medical Affairs and Dean, UM Miller School of Medicine Chief Executive Officer, University of Miami Health System	Support Letter
Savita Pahwa, M.D.	Director, Miami Center for Aids Research (CFAR)	Support Letter
Michael Kolber, M.D.	Director, Comprehensive Aids Program (CAP)	Support Letter
Mary Ann Sprinkle	Associate Vice President, Medical Development & Alumni Relations	Support Letter
Roy E. Weiss, M.D., Ph.D.	Professor and Chairman, Department of Medicine	Support Letter
Thomas R. Malek, Ph.D.	Professor & Vice Chair, Department of Microbiology & Immunology	Support Letter
Judy Schaechter, M.D., MBA	Interim Chair, Department of Pediatrics	Support Letter
Stephen D. Nimer, M.D.	Director, Sylvester Comprehensive Cancer Center	Support Letter
Richard J. Cote, M.D., FRCPath, FCAP	Professor and Joseph R. Coulter Jr. Chair, Department of Pathology Professor, Department of Biochemistry and Molecular Biology Director, Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute	Support Letter
José Szapocznik, Ph.D.	Professor and Chair, Department of Public Health Sciences Director, Miami Clinical & Translational Science Institute Director, Center for Family Studies	Support Letter

August 13, 2014

Tomas Salerno, M.D.
Chair, Faculty Senate
University of Miami
Ashe Building, Suite #325
1252 Memorial Drive
Coral Gables, FL 33146

Re: Council Approved a Proposal for an Establishment of an AIDS Institute

Dear Dr. Tomas Salerno,

This is to inform the Faculty Senate that the Medical School Faculty Council met on August 12th, 2014 to review the *Proposal for an Establishment of an AIDS Institute*.

The UM AIDS Institute will act as an umbrella for the coordination and enhancement of AIDS-related research, clinical, outreach, and philanthropic activities. The institute will drive efforts to secure philanthropic and state support.

The council members voted to *approve* the proposal.

Respectfully submitted,



Carl Schulman, M.D., M.S.P.H., Ph.D.
Speaker, Medical Faculty Council

Pascal J. Goldschmidt, M.D.
Senior Vice President for Medical Affairs and Dean
Chief Executive Officer, University of Miami Health System

MEMORANDUM

To: Robyn Hardeman
Secretary of the Faculty Senate

From: Pascal J. Goldschmidt, M.D.
Senior Vice President for Medical Affairs and Dean

Date: June 16, 2014

Subject: Support for the HIV/AIDS Institute



This memo is to request support from the University of Miami Faculty Senate to approve the creation of the HIV/AIDS Institute at the Miller School of Medicine. The establishment of the HIV/AIDS Institute is the next step in the evolution of the Miller School's long standing activities in HIV/AIDS treatment and research.

UM doctors began to see patients with immune system disorders at the earliest stages of the AIDS epidemic and in 1983 UM physicians published the first description of AIDS in heterosexual patients in the *Annals of Internal Medicine*. Both the research and clinical care for HIV/AIDS patients grew in parallel over the following three decades. The Miller School created the UM Comprehensive AIDS Program (CAP), a primarily clinical program that coordinates data collection, HIV surveillance, community outreach, and funding for HIV care from sources such as Ryan White Title I and the State of Florida. The Miller School's research efforts in HIV/AIDS are significant and culminated with the designation as a Center for AIDS Research (CFAR), a multi-million dollar grant from the National Institute of Allergy and Infectious Diseases. UM remains the only NIH-funded AIDS research center in Florida.

Our efforts in HIV/AIDS are strong but siloed. In order to move these important initiatives to the next level we need an integrated infrastructure that combines research and clinical care with advocacy and philanthropy. The formalization of the HIV/AIDS Institute will accomplish that goal. The School is fully committed to the success of the HIV/AIDS Institute and will continue to direct the facilities and administrative costs recovered via the CFAR to support these initiatives. I fully endorse the creation of the HIV/AIDS Institute without hesitation or reservation and look forward to the Senate's approval of this vital institute.

PJG/mml

UNIVERSITY OF MIAMI
MILLER SCHOOL
of MEDICINE



Department of Microbiology and Immunology
Miami Center for AIDS Research

Bachelor Children's Research Institute
PO BOX 016960 (R-138)
Miami, FL 33101

Ph: 305 243 7732
Fax: 305 243 7711

To: Robyn Hardeman
Secretary of the Faculty Senate

From: Savita Pahwa, MD
Director, Miami Center for AIDS Research (CFAR)

Date: June 3, 2014

Subject: HIV/AIDS Institute

This memo is to offer my support for the University of Miami Faculty Senate to approve the creation of the HIV/AIDS Institute at the Miller School of Medicine.

Florida ranks second in the nation in the cumulative number of AIDS cases and in the number of estimated AIDS diagnoses of children greater than 13 years of age. As the Director of the Miami Center for AIDS Research (CFAR), I have seen the School's HIV/AIDS initiatives flourish. In 2007 we became the first NIH-funded Developmental Center for AIDS Research in Florida, and in 2012, we successfully competed for the prestigious designation of the Miami Center for AIDS Research, joining a class of 17 full CFARs in the nation.

The Miami CFAR's mission is to advance HIV/AIDS research by providing scientific leadership and developing an infrastructure that fosters integration of basic and clinical sciences including behavioral/social sciences, promotes education and mentorship, and partners with the community to prevent, treat and cure HIV/AIDS. At this time, to achieve even greater success and energize HIV/AIDS science, we must enhance the original CFAR structure and partner with the clinical and advocacy efforts at the School. By creating an integrated, interdisciplinary institute focused on HIV/AIDS, we will be better positioned for philanthropy efforts at the Miller School, and thereby advance the research directives of the Miami CFAR.

The CFAR is fully on board with the creation of this Institute including the leveraging of CFAR infrastructure. Formalization of the partnership of the CFAR with the AIDS Institute will ensure the continued success of the HIV/AIDS initiatives at the Miller School.

Sincerely,

A handwritten signature in cursive script that reads "Savita Pahwa".

Savita Pahwa, M.D.,
Director, Miami Center for AIDS Research
Professor, Microbiology and Immunology
(Pediatrics and Medicine)
University of Miami Miller School of Medicine



UNIVERSITY OF MIAMI
MILLER SCHOOL
of MEDICINE

To: Robyn Hardeman
Secretary of the Faculty Senate

From: Dr. Michael Kolber
Director, Comprehensive AIDS Program (CAP)

Date: June 3, 2014

Subject: HIV/AIDS Institute

In my capacity as the Director of the Comprehensive AIDS Program (CAP), I am pleased to offer my strong support for the creation of the HIV/AIDS Institute at the Miller School of Medicine.

The CAP began in 1988 in an effort to manage the clinical aspects of HIV/AIDS care. Today the CAP facilitates quality HIV/AIDS healthcare services for over three thousand patients within Miami Dade County and provides specialty care services, mental health services, and linkage to care. In addition, Ryan White Medical Case Management, PAC Waiver and other HIV/AIDS related services are offered under the Comprehensive AIDS umbrella.

Although the CAP has a solid working relationship with the Miami Center for AIDS Research (CFAR), there is significant opportunity to align the HIV/AIDS efforts under the proposed Institute structure.

The creation of an integrated, interdisciplinary institute focused on HIV/AIDS will provide the infrastructure we have heretofore lacked at the Miller School. The proposed Institute will undoubtedly provide a nidus for the School's HIV/AIDS clinical care, outreach, translational and clinical research with clear linkage to the advocacy and philanthropic efforts.

The CAP strongly supports the proposed HIV/AIDS Institute and I fully endorse its creation without hesitation or reservation.

Sincerely,

Michael A. Kolber, Ph.D., M.D.
Professor of Medicine DoM
Director, Comprehensive AIDS Program UMMSM
Clinical Director, Adult HIV Services, Div of Infectious Diseases, DoM



UNIVERSITY OF MIAMI
MILLER SCHOOL
of MEDICINE

To: Robyn Hardeman
Secretary of the Faculty Senate

From: Mary Ann Sprinkle
Associate Vice President, Medical Development and Alumni Relations

Date: June 4, 2014

Subject: Support for the HIV/AIDS Institute

This memo is to demonstrate my support for the creation of the HIV/AIDS Institute at the Miller School of Medicine.

In my role as the Associate Vice President of Medical Development and Alumni Relations at the Miller School, I have the privilege of working with our doctors and scientists to develop relationships with the community. The Miller School has a long and proud history of activities related to HIV/AIDS. From the very beginning of the HIV/AIDS epidemic, UM physicians and researchers have been on the front lines - at the bedside, in the laboratory, and in the community. UM's commitment to patient care, groundbreaking research, and passionate advocacy continues today.

The creation of an integrated and interdisciplinary home for HIV/AIDS at the Miller School will position us for more coordinated approaches for philanthropy. One of the most significant challenges we have had in developing philanthropy around our HIV/AIDS work has been the lack of a framework that includes all the diverse HIV/AIDS initiatives. The creation of this Institute will overcome that hurdle.

My office has worked closely with Dr. Mario Stevenson in developing a relationship with the Palm Beach Infectious Disease Institutes and I offer the full collaboration of the Office of Medical Development in the HIV/AIDS Institute philanthropy efforts. I fully endorse the creation of the HIV/AIDS Institute and look forward to fostering strong and fruitful collaborations and relationships.

Associate Vice President for Medical Development and Alumni Relations
Office of Medical Development and Alumni Relations

Post Office Box 016960 (R-100) | Miami, Florida 33101
Phone: 305-243-6256 | Fax: 305-243-3904

Memorandum

To: Robyn Hardeman
Secretary of the Faculty Senate

From: Roy E. Weiss, M.D., Ph.D.
Professor and Chairman, Department of Medicine

Date: August 13, 2014

Subject: HIV/AIDS Institute



This memo is to express my concurrence for the creation of the HIV/AIDS Institute at the University of Miami Miller School of Medicine. The Faculty Senate will be voting on whether to approve the implementation of this interdisciplinary Institute and this letter is to demonstrate the Department of Medicine's strong support. Prof. Mario Stevenson presented the HIV/AIDS Institute proposal at a Department of Medicine faculty meeting on July 14, 2014. The initial concerns of the faculty regarding whether incremental resources will be required or resources currently going elsewhere will be shifted towards the institute were dispelled by Prof. Stevenson. Following an active discussion, the faculty voted unanimously to support the establishment of the Institute.

The rationale for the formation of an HIV/AIDS Institute is to provide an interdisciplinary home for the School's scholarly, clinical and advocacy efforts in HIV/AIDS. The lack of a nidus for HIV/AIDS activities has been a significant barrier to integrating the various efforts in the HIV/AIDS arena across the School.

The Department of Medicine enthusiastically supports this proposal and we are excited to be a part of what will surely galvanize HIV/AIDS work at the Miller School of Medicine and will undoubtedly improve the health of our patients with HIV/AIDS.

UNIVERSITY OF MIAMI
MILLER SCHOOL
of MEDICINE

THE MIAMI CENTER FOR AIDS RESEARCH




Department of Microbiology & Immunology

Batchelor Children's Research Institute
PO BOX 016960 (R-130)
Miami, FL 33101

Ph: 305 243 7732
Fax: 305 243 7711

To: Robyn Hardeman
Secretary of the Faculty Senate

From: Thomas R. Malek, Ph.D. 
Professor and Vice Chair, Department of Microbiology & Immunology

Date: August 11, 2014

Subject: Support for the HIV/AIDS Institute


On behalf of Dr. Eckhard Podack, Chair and of myself, Vice Chair of the Department of Microbiology & Immunology, we would like to express our enthusiasm for the creation of the HIV/AIDS Institute at the University of Miami Miller School of Medicine and to encourage the Faculty Senate to approve its implementation. Dr. Mario Stevenson presented the HIV/AIDS Institute proposal at a Department of Microbiology & Immunology faculty meeting on August 7, 2014 and the faculty vote resulted in support of its establishment. Dr. Stevenson, Ph.D., is a member of the NIH supported "Center for AIDS Research (CFAR)" assisting the CFAR Director, Dr. Savita Pahwa, M.D., in expanding public recognition of the importance of AIDS/HIV related research and in leveraging NIH recognition and support for further public and philanthropic funding.

The formation of an HIV/AIDS Institute, with CFAR leadership, will provide a larger interdisciplinary effort for the School's research, clinical and advocacy efforts in HIV/AIDS.

The creation of an integrated and interdisciplinary Institute for HIV/AIDS at the Miller School will also position the CFAR for a more coordinated approach for philanthropy. One of the most significant challenges in developing philanthropy around our HIV/AIDS work within the CFAR, has been the lack of promotion of public awareness and a minimum of efforts for fund raising through philanthropy. The creation of the HIV/AIDS Institute will overcome that hurdle and help provide funding for all types of HIV/AIDS research including virological and immunological research.

Our HIV/AIDS initiatives within the CFAR at the Miller School of Medicine are robust but we require more coordination and synchronization to realize our full potential. The Department of Microbiology & Immunology, having sponsored the application for the CFAR, enthusiastically supports this proposal and we are thrilled to be a part of what will surely galvanize and strengthen HIV/AIDS work at the Miller School.

To: Robyn Hardeman
Secretary of the Faculty Senate

From: Judy Schaechter, MD, MBA 
Interim Chair, Department of Pediatrics

Date: June 16, 2014

Subject: HIV/AIDS Institute

This memo is to request support from the University of Miami Faculty Senate to approve the creation of the HIV/AIDS Institute at the Miller School of Medicine which will cover the lifespan – from perinatal, childhood, adolescence, parenting, adulthood, and into advanced aging.

There is a need for an integrated, interdisciplinary institute that offers the expertise, infrastructure, and resources necessary to organize and energize HIV/AIDS science and advance translational and clinical research in HIV/AIDS at the Miller School of Medicine.

Our HIV/AIDS initiatives at the Miller School of Medicine are strong and diverse but not well synchronized. Better communication, cooperation, and coordination through the proposed Institute will form and foster interdisciplinary research and clinical care in HIV/AIDS and position the HIV/AIDS programs—both pediatric and adult—at the Miller School of Medicine for the next chapter in their impressive histories.


I look forward to the Department of Pediatrics' full cooperation as a partner in the success of this important Institute – in its creation, governance, growth, and sustainability. I am looking forward to fostering strong and fruitful collaborations and relationships which will benefit the work of the HIV/AIDS Institute and the University of Miami as a whole.



MEMORANDUM

DATE: July 22, 2014

TO: Robyn Hardeman
Secretary of the Faculty Senate

FROM: Stephen D. Nimer, M.D. 
Director, Sylvester Comprehensive Cancer Center

SUBJECT: Support for the HIV/AIDS Institute

This memo is to demonstrate my support for the creation of the HIV/AIDS Institute at the Miller School of Medicine. The Miller School has long-standing and interdisciplinary efforts in HIV/AIDS and the creation of an Institute that integrates clinical care, research and advocacy efforts will position the Miller School for even more initiatives in this important arena.

As the Director of the Sylvester Comprehensive Cancer Center, I am particularly excited about the potential for the new Institute. The Viral Oncology Program at Sylvester was established as one of the nation's most distinctive programs in 1998 by the late Dr. William Harrington, Jr., a leading authority on viral-induced cancers. Preventing, treating and understanding the etiology of HIV-associated malignancies remains a priority for the Program.

Sylvester researchers are active in the CFAR and would benefit from the proposed Institute structure as it will facilitate and foster interdisciplinary research and clinical care in HIV/AIDS and position the HIV/AIDS programs at the Miller School for better coordinated efforts for advocacy and support from the State of Florida. Dr. Mario Stevenson's success in getting directed dollars for HIV/AIDS research is a clear indication of the potential for this new Institute.

I offer the full cooperation of the Sylvester Comprehensive Cancer Center in supporting the success of this important institute. I fully endorse the creation of the HIV/AIDS Institute and look forward to fostering strong and fruitful collaborations and relationships.

Richard J. Cote, M.D., FRCPath, FCAP

Professor and Joseph R. Coulter Jr. Chair, Department of Pathology
Professor, Department of Biochemistry and Molecular Biology
Chief of Pathology, Jackson Memorial Hospital
Director, Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute

Department of Pathology
Clinical Research Building
1120 NW 14th Street (R-5), Suite 1416
Miami, FL 33136
Ph: (305) 243-1111 • Fax: (305) 243-1115
rcote@med.miami.edu

Memorandum

To: Robyn Hardeman
Secretary of the Faculty Senate



From: Richard J. Cote, M.D., FRCPath, FCAP
Professor and Joseph R. Coulter Jr. Chair, Department of Pathology
Professor, Department of Biochemistry and Molecular Biology
Chief of Pathology, Jackson Memorial Hospital
Director, Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute

Date: September 2, 2014

Subject: Support for the HIV/AIDS Institute

This memo is to document my strong support for the creation of the HIV/AIDS Institute at the University of Miami Miller School of Medicine and to encourage the Faculty Senate to approve its implementation. Dr. David Watkins, representing Dr. Mario Stevenson, presented the HIV/AIDS Institute proposal at a Department of Pathology faculty meeting on July 17, 2014 and the faculty voted unanimously to support its establishment.

There is an urgent need for an integrated, interdisciplinary institute that offers the expertise, infrastructure, and resources necessary to organize and energize HIV/AIDS science and advance translational and clinical research in HIV/AIDS at the Miller School.

Our HIV/AIDS initiatives at the Miller School are strong and diverse but not synchronized. The proposed institute will form and foster interdisciplinary research and clinical care in HIV/AIDS and position the HIV/AIDS programs at the Miller School for the next chapter in their impressive history.

I offer the full cooperation of the Department of Pathology in supporting the success of this important institute. I fully endorse the creation of the HIV/AIDS Institute and look forward to fostering strong and fruitful collaborations and relationships.



UNIVERSITY OF MIAMI
MILLER SCHOOL
of MEDICINE

To: Robyn Hardeman
Secretary of the Faculty Senate

From: José Szapocznik, Ph.D.
Professor and Chair, Department of Public Health Sciences
Director, Miami Clinical Translational Science Institute
Director, Center for Family Studies

Date: August 14, 2014

Subject: Support for the HIV/AIDS Institute

This memo is to demonstrate my support for the creation of the HIV/AIDS Institute at the University of Miami Miller School of Medicine and to encourage the Faculty Senate to approve its implementation. Dr. Mario Stevenson presented the HIV/AIDS Institute proposal at a Department of Public Health Sciences faculty meeting on August 13, 2014 and the faculty voted unanimously to support its establishment.

The formation of an HIV/AIDS Institute will provide an interdisciplinary home for the School's research, clinical and advocacy efforts in HIV/AIDS. The lack of a nidus for HIV/AIDS activities has been a significant barrier to integrating the various efforts in the HIV/AIDS arena across the School.

Several faculty members in the Department of Public Health Sciences are actively dedicated to HIV/AIDS research and the establishment of this Institute will undoubtedly foster interdisciplinary research and position the HIV/AIDS programs at the Miller School for better coordinated efforts to obtain better support for directed funding for HIV/AIDS research.

As chair of the Department of Public Health Sciences, I enthusiastically support this proposal and we look forward to fostering strong and fruitful collaborations which will surely further stimulate HIV/AIDS work at the Miller School.

Department of Public Health Sciences
Clinical Research Building (CRB), 9th & 10th Floors (Locator code R669)
1120 NW 14th Street • Miami, FL 33136
Phone: (305) 243-8331
publichealth.med.miami.edu

Faculty Senate Office

From: Faculty Senate Office
Sent: Wednesday, March 04, 2015 5:51 PM
To: Freyre, Maria Betty; Goldschmidt, Pascal J.; Stevenson, Mario; Van der Put, Elaine
Cc: Robitaille, Magaly; Faculty Senate Office; Senate Chair
Subject: FW: 2014-22(B)
Attachments: 20150304101931411.pdf

Attached is your copy of Legislation #2014-22(B) – "Establish an HIV/AIDS Institute at the University of Miami Miller School of Medicine" that is pending approval by the President. You will be sent a copy of the final legislation once it has been approved.

This may also require Board of Trustees approval, but that is not determined by this office.

Regards,
Robyn Hardeman

UNIVERSITY
OF MIAMI
FACULTY SENATE
Robyn Hardeman
Secretary of the Faculty Senate
325 Ashe Admin. Building
1252 Memorial Drive
Coral Gables, FL 33146
facsen@miami.edu
web site: www.miami.edu/fs
P: 305-284-3721
F: 305-284-5515

-----Original Message-----

From: facsen@donotreply.edu [mailto:facsen@donotreply.edu]
Sent: Wednesday, March 04, 2015 10:20 AM
To: Faculty Senate Office
Subject: 2014-22(B)

This E-mail was sent from "RNP11652D" (Aficio MP C3300).

Scan Date: 03.04.2015 10:19:31 (-0500)
Queries to: facsen@donotreply.edu

Faculty Senate Office

From: Faculty Senate Office
Sent: Tuesday, March 10, 2015 11:01 AM
To: Freyre, Maria Betty; Goldschmidt, Pascal J.; Stevenson, Mario; Van der Put, Elaine
Cc: Robitaille, Magaly; Senate Chair; Ransford, Daru (dransford@med.miami.edu)
Subject: RE: 2014-22(B)
Attachments: 2014-22B-MSOM-AIDS-HIV-Institute.pdf

Attached is your copy of approved Legislation #2014-22(B) – "Establish an HIV/AIDS Institute at the University of Miami Miller School of Medicine."

We wish you and the Institute personnel great success as you work to further the mission of the University of Miami through this important enterprise.

Please be aware that as required by section B6.6 of the Faculty Manual, a copy of the operating rules must be maintained in the files of the Faculty Senate. Therefore it is important that you send to the Senate office any such amendments or changes in the rules. The Faculty Manual also provides that the Executive Vice-President and Provost shall consult with the dean of the host school of an approved Center or Institute at five year intervals to determine whether the unit remains active and shall report to the Faculty Senate the names of those that should be disestablished.

Again, we are happy to have assisted you in the creation of the Institute.

Regards,
Robyn

UNIVERSITY
OF MIAMI
FACULTY SENATE
Robyn Hardeman
Secretary of the Faculty Senate
325 Ashe Admin. Building
1252 Memorial Drive
Coral Gables, FL 33146
facsen@miami.edu
web site: www.miami.edu/fs
P: 305-284-3721
F: 305-284-5515

-----Original Message-----

From: Faculty Senate Office
Sent: Wednesday, March 04, 2015 5:51 PM
To: Freyre, Maria Betty; Goldschmidt, Pascal J.; Stevenson, Mario; Van der Put, Elaine
Cc: Robitaille, Magaly; Faculty Senate Office; Senate Chair
Subject: FW: 2014-22(B)